Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
George G Zhanel, Tamiko Hisanaga, Aleksandra Wierzbowski & Daryl J Hoban. (2006) Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia. Therapeutics and Clinical Risk Management 2:1, pages 59-75.
Read now
Read now
Carman A. Ciervo & Jun Shi. (2005) Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. Current Medical Research and Opinion 21:10, pages 1641-1650.
Read now
Read now
George G Zhanel, Tamiko Hisanaga, Kim Nichol, Aleksandra Wierzbowski & Daryl J Hoban. (2003) Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opinion on Emerging Drugs 8:2, pages 297-321.
Read now
Read now
Articles from other publishers (22)
Ling Ye, Jiaxing Zhang, Wei Xiao & Shuwen Liu. (2020) Efficacy and mechanism of actions of natural antimicrobial drugs. Pharmacology & Therapeutics 216, pages 107671.
Crossref
Crossref
Eric Wenzler, Kelly Sprandel-Harris & Keith A. Rodvold. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
87
162
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
425
428
.
Sarfaraz K. Niazi. 2014. Handbook of Bioequivalence Testing. Handbook of Bioequivalence Testing
756
787
.
X. WANG, Y. F. TAO, L. L. HUANG, D. M. CHEN, S. Z. YIN, A. IHSAN, W. ZHOU, S. J. SU, Z. L. LIU, Y. H. PAN & Z. H. YUAN. (2011) Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. Journal of Veterinary Pharmacology and Therapeutics 35:3, pages 282-289.
Crossref
Crossref
Md L T Vieira, P Zhao, E G Berglund, K S Reynolds, L Zhang, L J Lesko & S-M Huang. (2012) Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor. Clinical Pharmacology & Therapeutics 91:4, pages 700-708.
Crossref
Crossref
Mathieu S. Bolhuis, Prashant N. Panday, Arianna D. Pranger, Jos G. W. Kosterink & Jan-Willem C. Alffenaar. (2011) Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams. Pharmaceutics 3:4, pages 865-913.
Crossref
Crossref
Jerry M. Zuckerman, Fozia Qamar & Bartholomew R. Bono. (2011) Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline). Medical Clinics of North America 95:4, pages 761-791.
Crossref
Crossref
Jerry M. Zuckerman, Fozia Qamar & Bartholomew R. Bono. (2009) Macrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline. Infectious Disease Clinics of North America 23:4, pages 997-1026.
Crossref
Crossref
Hossam Al-Tatari, Nahed Abdel-Haq, Pimpanada Chearskul & Basim Asmar. (2006) Antibiotics for treatment of resistant gram-positive coccal infections. The Indian Journal of Pediatrics 73:4, pages 323-334.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
1976
1977
.
Christina Lippert, Seth Gbenado, Chunfu Qiu, Bruce Lavin & Steven J. Kovacs. (2013) The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole. The Journal of Clinical Pharmacology 45:9, pages 1025-1031.
Crossref
Crossref
Megan Nguyen & Eunice P. Chung. (2005) Telithromycin: The first ketolide antimicrobial. Clinical Therapeutics 27:8, pages 1144-1163.
Crossref
Crossref
Nishaminy Kasbekar & Pinak S. Acharya. (2005) Telithromycin: The first ketolide for the treatment of respiratory infections. American Journal of Health-System Pharmacy 62:9, pages 905-916.
Crossref
Crossref
Thomas M. FileJr.Jr.. (2005) Telithromycin new product overview. Journal of Allergy and Clinical Immunology 115:2, pages S361-S373.
Crossref
Crossref
Jun Shi, Guy Montay & Vijay O Bhargava. (2005) Clinical Pharmacokinetics of Telithromycin, the First Ketolide Antibacterial. Clinical Pharmacokinetics 44:9, pages 915-934.
Crossref
Crossref
Jerry M Zuckerman. (2004) Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infectious Disease Clinics of North America 18:3, pages 621-649.
Crossref
Crossref
Jun Shi, Guy Montay, Sunny Chapel, Pierre Hardy, Jeffrey S. Barrett, Marshall Sack, Thomas Marbury, Suzanne K. Swan, Ramon Vargas, Violette Leclerc, Bruno Leroy & Vijay O. Bhargava. (2013) Pharmacokinetics and Safety of the Ketolide Telithromycin in Patients with Renal Impairment. The Journal of Clinical Pharmacology 44:3, pages 234-244.
Crossref
Crossref
Keri Wellington & Stuart Noble. (2004) Telithromycin. Drugs 64:15, pages 1683-1694.
Crossref
Crossref
Alexander Imhof. 2004.
251
275
.
Fritz Sörgel, Cornelia Landersdorfer & Jürgen Bulitta. (2004) Zur Pharmakokinetik von Linezolid und Telithromycin: Zwei neue Antibiotika mit besonderen Eigenschaften. Pharmazie in unserer Zeit 33:1, pages 28-36.
Crossref
Crossref
C. Carbon, S. Moola, I. Velancsics, B. Leroy, M. Rangaraju & P. Decosta. (2003) Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clinical Microbiology and Infection 9:7, pages 691-703.
Crossref
Crossref